Curevac N.V. (CVAC) Stock Price, Quote & News

Company Profile

As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human c...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 7071 9883 0

Address:

Friedrich-Miescher-Strasse 15, Tübingen, Germany

ArcaneFoxx Jan. 4 at 3:46 AM

$CVAC Consensus Rating: Hold analysts on average recommend holding the stock rather than a clear Buy or Sell…

0 · Reply

khmerxbxboi Dec. 26 at 3:23 AM

$CVAC = Santa Rally !!!

0 · Reply

OnlyFibs Dec. 26 at 1:41 AM

I'm following the footprints on $CVAC—the 10-day VWAP is finally turning into a launchpad. 🏗️⚡ Setup: Perfect 8h pivot bottom; RSI is waking up from the dead (31) meaning the spring is officially loaded. Unusual Flow: 13F filings show Citadel and Susquehanna shifting heavily into calls (+136%) as the merger floor solidifies. 🏗️ Target: Clearing the $4.37 wall triggers the gap-fill to the $6.83 bull targets. 📈 Safety: Stop below the $4.07 structural floor. 🧱 The BioNTech moat is absorbing the competition. Don't fight the $101.88 exchange reference price. 🚢📉 #hovdid

0 · Reply

G20Gains Dec. 25 at 2:51 PM

$CVAC Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Cash flow visibility will determine how patient investors remain. A series of confirmed wins might reduce the required risk premium. In short, this remains an execution‑driven story with meaningful but conditional upside.

0 · Reply

OnlyFibs Dec. 24 at 12:51 AM

$CVAC: One Last Momentum Play? 🎯 Action: Up +2.18% today as liquidity dries up ahead of the Jan buyout Catalyst: Compulsory acquisition in Jan 2026 will clean up remaining 13.2% of float Support: Rock solid at $3.80; Bulls holding the red trendline PT: Fair value sitting near the $5.43 analyst median for those still holding RSI is screaming oversold—watch for a final liquidity grab before it’s gone. 🔋💎 #hovdid

0 · Reply

khmerxbxboi Dec. 23 at 8:05 PM

$CVAC = $$$

0 · Reply

khmerxbxboi Dec. 22 at 4:59 PM

$CVAC = Sleeping ...

0 · Reply

taxplanr Dec. 19 at 11:39 AM

$BNTX and now all the trials will also have to show there is no shedding for approval Add more expenses for failure on top of $CVAC losses

0 · Reply

khmerxbxboi Dec. 17 at 6:53 PM

$CVAC = loading time my friends !!!

0 · Reply

Tom2772 Dec. 16 at 9:31 PM

$CVAC The P/E ratio will show its potential for improvement through synergies as early as next year. Most importantly, there will be no more internal legal disputes and 1,000 new patents for $BNTX . CureVac's expertise should help BioNTech get closer to the approval of mRNA-based cancer therapies. They are just one step away. This is a major undertaking, and I am convinced it will be worth significantly more than $1.25 billion in the long run.

1 · Reply

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

BNTX

Nov 28, 2025, 3:33 AM EST - 5 weeks ago

CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript

Nov 25, 2025, 7:05 PM EST - 5 weeks ago

CureVac Announces Voting Results of Extraordinary General Meeting

Nov 24, 2025, 7:30 AM EST - 6 weeks ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

Oct 1, 2025, 5:26 AM EDT - 3 months ago

CureVac: The Hidden Value Of The mRNA Wallet

Aug 15, 2025, 7:50 AM EDT - 5 months ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

Aug 7, 2025, 9:00 PM EDT - 5 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

BNTX PFE

Jun 24, 2025, 4:35 PM EDT - 6 months ago

CureVac Announces Voting Results of General Meeting

Jun 12, 2025, 12:05 PM EDT - 7 months ago

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

BA ORCL

Jun 12, 2025, 11:07 AM EDT - 7 months ago

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BNTX

Jun 12, 2025, 7:11 AM EDT - 7 months ago

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

BNTX

Jun 12, 2025, 7:03 AM EDT - 7 months ago

BioNTech to acquire CureVac in $1.25 billion all-stock deal

BNTX

May 20, 2025, 7:15 AM EDT - 8 months ago

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

May 15, 2025, 4:45 PM EDT - 8 months ago

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

Apr 10, 2025, 12:59 PM EDT - 9 months ago

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

Apr 10, 2025, 7:30 AM EDT - 9 months ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Apr 8, 2025, 7:25 AM EDT - 9 months ago

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Apr 7, 2025, 7:15 AM EDT - 9 months ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Mar 28, 2025, 12:45 PM EDT - 10 months ago

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

BNTX

Mar 28, 2025, 8:58 AM EDT - 10 months ago

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

Mar 27, 2025, 6:22 PM EDT - 10 months ago

European Patent Office declares CureVac mRNA patent valid

Mar 27, 2025, 4:30 PM EDT - 10 months ago

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Feb 18, 2025, 7:15 AM EST - 11 months ago

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

Jan 8, 2025, 4:55 PM EST - 1 year ago

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Nov 12, 2024, 3:08 PM EST - 1 year ago

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:20 AM EST - 1 year ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Nov 4, 2024, 7:20 AM EST - 1 year ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Nov 4, 2024, 7:15 AM EST - 1 year ago

CureVac to Present at the 12th International mRNA Health Conference

Oct 28, 2024, 8:10 AM EDT - 1 year ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 8, 2024, 5:50 AM EDT - 1 year ago

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

BNTX PFE

Sep 13, 2024, 8:15 AM EDT - 1 year ago

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Sep 12, 2024, 7:15 AM EDT - 1 year ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 9, 2024, 7:15 AM EDT - 1 year ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Aug 15, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Aug 15, 2024, 7:20 AM EDT - 1 year ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024, 7:15 AM EDT - 1 year ago

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Jul 11, 2024, 7:15 AM EDT - 1 year ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Jul 3, 2024, 10:18 AM EDT - 1 year ago

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

GSK

Jul 3, 2024, 7:53 AM EDT - 1 year ago

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

GSK

Jul 3, 2024, 2:40 AM EDT - 1 year ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK

Jul 3, 2024, 2:40 AM EDT - 1 year ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Jul 3, 2024, 2:26 AM EDT - 1 year ago

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK

Apr 24, 2024, 3:12 PM EDT - 1 year ago

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Apr 18, 2024, 7:15 AM EDT - 1 year ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

ArcaneFoxx Jan. 4 at 3:46 AM

$CVAC Consensus Rating: Hold analysts on average recommend holding the stock rather than a clear Buy or Sell…

0 · Reply

khmerxbxboi Dec. 26 at 3:23 AM

$CVAC = Santa Rally !!!

0 · Reply

OnlyFibs Dec. 26 at 1:41 AM

0 · Reply

G20Gains Dec. 25 at 2:51 PM

0 · Reply

OnlyFibs Dec. 24 at 12:51 AM

0 · Reply

khmerxbxboi Dec. 23 at 8:05 PM

$CVAC = $$$

0 · Reply

khmerxbxboi Dec. 22 at 4:59 PM

$CVAC = Sleeping ...

0 · Reply

taxplanr Dec. 19 at 11:39 AM

$BNTX and now all the trials will also have to show there is no shedding for approval Add more expenses for failure on top of $CVAC losses

0 · Reply

khmerxbxboi Dec. 17 at 6:53 PM

$CVAC = loading time my friends !!!

0 · Reply

Tom2772 Dec. 16 at 9:31 PM

1 · Reply

Roberto24 Dec. 12 at 1:26 AM

$CVAC

0 · Reply

Roberto24 Dec. 12 at 1:21 AM

$CVAC when reversal

0 · Reply

taxplanr Dec. 11 at 2:45 PM

$BNTX maybe it was just a bad time to take on more overhead and operational losses with $CVAC 🤔

0 · Reply

RealDea1bull Dec. 6 at 1:52 PM

$CVAC

0 · Reply

RealDea1bull Dec. 6 at 1:50 PM

$CVAC not even moving a littlw just frozen

0 · Reply

RealDea1bull Dec. 6 at 1:50 PM

$CVAC 6k watchers

0 · Reply

RealDea1bull Dec. 6 at 1:50 PM

$CVAC

0 · Reply

taxplanr Dec. 3 at 4:09 PM

$BNTX $CVAC when does that ACIP meeting start?

0 · Reply

taxplanr Dec. 2 at 3:02 PM

$BNTX $CVAC game of chicken with ACIP board meeting GLTA

0 · Reply

taxplanr Dec. 2 at 3:32 AM

$BNTX $MRNA $PFE just another sharp shooter for the end of the week firing squad $CVAC https://justthenews.com/politics-policy/health/rfk-jr-appoints-former-acip-chairman-martin-kulldorff-senior-hhs-post?utm_source=mux&utm_medium=social-media&utm_campaign=social-media-autopost

0 · Reply

taxplanr Dec. 1 at 3:07 PM

$CVAC what a bummer

1 · Reply

taxplanr Dec. 1 at 2:26 PM

I tried to warn $CVAC shareholders If you still think malignantRNA is viable get used to the dumping by Biontech insiders

0 · Reply

Market Cap	960.17M
Revenue (ttm)	579.12M
Net Income (ttm)	175.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	30.30%
Debt to Equity Ratio	0.00

Volume	2,792,900
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	224.34M
Stochastic %K	N/A
Beta	1.77
Analysts	Hold
Price Target	$5.32